Manning & Napier Advisors’s Charles River Laboratories CRL Stock Holding History

Manning & Napier Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.16K	Buy	+14	New	+$2.49K	﹤0.01%	660

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Manning & Napier Advisors's CRL Position: Q2 2026 in Review

Manning & Napier Advisors opened a new position in Charles River Laboratories (CRL) in Q2 2026: 14 shares worth $3.16K. The stake represents ﹤0.01% of the portfolio and ranks #660 among its holdings.

563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Manning & Napier Advisors held 14 shares of Charles River Laboratories worth $3.16K as of Q2 2026.
Charles River Laboratories was a new Manning & Napier Advisors position in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #660 holding.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.